Regenxbio Inc (NASDAQ: RGNX) kicked off on Monday, down -6.76%% from the previous trading day, before settling in for the closing price of $8.43. Over the past 52 weeks, RGNX has traded in a range of $5.03-$15.36.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -12.18% over the past five years. While this was happening, its average annual earnings per share was recorded 93.72%. With a float of $45.66 million, this company’s outstanding shares have now reached $50.12 million.
Let’s look at the performance matrix of the company that is accounted for 353 employees. In terms of profitability, gross margin is 76.54%, operating margin of -100.41%, and the pretax margin is -100.62%.
Regenxbio Inc (RGNX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Regenxbio Inc is 9.39%, while institutional ownership is 87.17%. The most recent insider transaction that took place on May 12 ’25, was worth 163,046. In this transaction Director of this company sold 20,602 shares at a rate of $7.91, taking the stock ownership to the 475,103 shares. Before that another transaction happened on May 12 ’25, when Company’s Director proposed sale 20,602 for $7.52, making the entire transaction worth $154,927.
Regenxbio Inc (RGNX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 93.72% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.05% during the next five years compared to -12.18% drop over the previous five years of trading.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
Take a look at Regenxbio Inc’s (RGNX) current performance indicators. Last quarter, stock had a quick ratio of 2.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.14, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach -1.51 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
Regenxbio Inc (NASDAQ: RGNX) saw its 5-day average volume 1.24 million, a positive change from its year-to-date volume of 1.08 million. As of the previous 9 days, the stock’s Stochastic %D was 7.67%.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 47.36%, which indicates a significant increase from 1.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 111.27% in the past 14 days, which was higher than the 100.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.65, while its 200-day Moving Average is $8.73. Nevertheless, the first resistance level for the watch stands at $8.27 in the near term. At $8.67, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.90. If the price goes on to break the first support level at $7.64, it is likely to go to the next support level at $7.41. The third support level lies at $7.01 if the price breaches the second support level.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
The company with the Market Capitalisation of 396.06 million has total of 50,160K Shares Outstanding. Its annual sales at the moment are 83,330 K in contrast with the sum of -227,100 K annual income. Company’s last quarter sales were recorded 89,010 K and last quarter income was 6,080 K.
